Genomind, based in King of Prussia, is a personalized medicine company bringing innovation to mental healthcare through genetic testing. In the award citation, Life Sciences Pennsylvania noted that “Genomind’s expert staff is comprised of pioneering researchers and thought leaders in psychiatry and neurology who specialize in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives.”
“We thank Life Sciences Pennsylvania for this important honor because it comes from our peers, most of whom have travelled the same road we are on now. We are proud of our corporate home and understand why Pennsylvania is considered the most attractive location in the United States for establishing a life sciences organization by industry leaders,” said Michael Koffler, CEO and President, Genomind.
In addition, Genomind recently has been recognized by Modern Healthcare as one of the best places to work, and was included in The Philadelphia 100® for being among the 100 fastest growing companies in the region.
Genomind is a personalized medicine company bringing innovation to mental healthcare through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology and specializes in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives. Learn more at www.genomind.com.
About the Genecept Assay®
The Genecept Assay is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes that have been selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. The Assay is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit hyperactivity disorder (ADHD), bipolar disorder, post-traumatic stress disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse, and has been shown in peer-reviewed published studies to improve patient outcomes and reduce overall medical costs. Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacogenomic consultation. Learn more at www.genomind.com
Vice President, Marketing and Corporate Communications